Every Form 4 that Aardvark Therapeutics, Inc. (AARD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AARD filings page.
Aardvark Therapeutics, Inc. (AARD) reported that its Chief Financial & Operating Officer, Sun Nelson, sold a total of 76,754 shares of common stock in open-market transactions on September 10 and September 11, 2026, at weighted-average prices around $5.00–$5.18 per share.
The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2026, indicating they were pre-arranged. A related footnote also notes that the reported holdings include 3,745 shares acquired through Aardvark Therapeutics' 2025 Employee Stock Purchase Plan on May 22, 2026.
Aardvark Therapeutics, Inc. (AARD) reported that director Jeffrey Chi received a grant of 44,964 stock options on August 14, 2026. The options have an exercise price of $6.54 per share and expire on August 14, 2036. According to the terms, the option vests in full on the earlier of August 14, 2027 or immediately prior to the company’s next Annual Meeting of Stockholders following the grant date, subject to his continuous service through the applicable vesting date.
Aardvark Therapeutics, Inc. (AARD) reported that director Susan E. Graf received a grant of 44,964 stock options to purchase Common Stock. The options have an exercise price of $6.54 per share, expire on August 14, 2036, and were awarded at no purchase price.
The options vest in full on the earlier of August 14, 2027 or immediately before the company’s next Annual Meeting of Stockholders following the grant date, subject to her continuous service through the vesting date. Following this grant, she holds 44,964 options directly.
Aardvark Therapeutics, Inc. (AARD) reported that director Roy D. Baynes received a grant of 44,964 stock options on August 14, 2026. The options have an exercise price of $6.54 per share, expire on August 14, 2036, and are held as a direct ownership position of 44,964 derivative securities. According to the grant terms, the option vests in full on the earlier of August 14, 2027 or immediately prior to the company’s next Annual Meeting of Stockholders following the grant date, subject to his continuous service through the applicable vesting date.
Aardvark Therapeutics, Inc. (AARD) reported that director Victor Edward Tong Jr received a grant of stock options for 44,964 shares of common stock at an exercise price of $6.54 per share. These options vest in full on the earlier of August 14, 2027 or immediately prior to the next Annual Meeting of Stockholders, subject to continuous service, and expire on August 14, 2036. Following this award, Tong holds 44,964 option shares from this grant.
Aardvark Therapeutics, Inc. reported that Chief Financial Officer Nelson Sun received a new stock option grant. On February 9, 2026, he was granted an option to buy 70,549 shares of common stock at an exercise price of $13.48 per share.
According to the vesting terms, one quarter of these option shares vest on February 9, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, so long as he remains in continuous service. After this grant, he beneficially owns 70,549 derivative securities directly.
Aardvark Therapeutics Chief Medical Officer receives stock option grant. Chief Medical Officer Manasi Jaiman was granted a stock option to buy 70,549 shares of Aardvark Therapeutics common stock at an exercise price of $13.48 per share on February 9, 2026.
The option vests over four years: one-quarter of the shares vest on February 9, 2027, and the remaining shares vest in equal monthly installments thereafter, subject to continued service. Following this grant, 70,549 derivative securities are beneficially owned directly.
Aardvark Therapeutics, Inc. director, chief executive officer, and 10% owner Lee Tien-Li reported receiving a stock option grant. On February 9, 2026, they were granted an option to buy 203,851 shares of common stock at an exercise price of $13.48 per share.
According to the vesting terms, one quarter of the option will vest on February 9, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, contingent on continued service. After this grant, 203,851 derivative securities are held directly.
Aardvark Therapeutics, Inc. reported an insider share purchase by its Chief Financial Officer, Nelson Sun. On 12/11/2025, he bought 3,000 shares of common stock in an open-market transaction coded "P" at a price of $14.40 per share. After this transaction, he beneficially owns 108,484 shares of Aardvark Therapeutics common stock in direct ownership.
Aardvark Therapeutics, Inc. reported an insider share purchase by its Chief Executive Officer, who is also a director and 10% owner. On 12/11/2025, the insider bought 7,000 shares of common stock at a price of $14.485 per share. Following this transaction, the insider beneficially owned 1,551,613 common shares directly and 1,474,028 common shares indirectly through a spouse, according to the filing.
Aardvark Therapeutics (AARD) reported an insider transaction. On 10/15/2025, the CEO, who is also a Director and 10% Owner, exercised 1,229 stock options (transaction code M) at $4.24 and acquired 1,229 common shares.
Following the transaction, beneficial ownership was 1,544,613 shares held directly and 1,474,028 shares held indirectly by spouse. The option award shows 40,566 derivative securities beneficially owned after the event, with an expiration date of 07/20/2034.
The filing notes a vesting schedule: 1/48th of the original option vested on 07/27/2024, with 1/48th vesting monthly thereafter, subject to continuous service.
Aardvark Therapeutics (AARD) reported an insider option exercise by its Chief Operating Officer. On 10/15/2025, the officer exercised stock options (code M) to acquire 1,250 shares of common stock at an exercise price of $4.24 per share, held directly. Following the transaction, 40,052 derivative securities (stock options) remained beneficially owned.
The option carries an expiration date of 07/20/2034. Per the footnote, 1/48th vested on 07/27/2024 and continues vesting in equal monthly installments, subject to continuous service.